|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LGALS7 |
Gene summary for LGALS7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LGALS7 | Gene ID | 3963 |
| Gene name | galectin 7 | |
| Gene Alias | GAL7 | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | P47929 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3963 | LGALS7 | CA_HPV_1 | Human | Cervix | CC | 1.91e-09 | -2.73e-01 | 0.0264 |
| 3963 | LGALS7 | CA_HPV_3 | Human | Cervix | CC | 4.16e-05 | -2.47e-01 | 0.0414 |
| 3963 | LGALS7 | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 7.11e-03 | -1.53e-01 | 0.0116 |
| 3963 | LGALS7 | CCII_1 | Human | Cervix | CC | 8.34e-03 | -2.73e-01 | 0.3249 |
| 3963 | LGALS7 | Tumor | Human | Cervix | CC | 5.89e-19 | 5.98e-01 | 0.1241 |
| 3963 | LGALS7 | sample3 | Human | Cervix | CC | 2.85e-11 | 3.77e-01 | 0.1387 |
| 3963 | LGALS7 | H2 | Human | Cervix | HSIL_HPV | 5.96e-05 | -2.32e-01 | 0.0632 |
| 3963 | LGALS7 | L1 | Human | Cervix | CC | 1.39e-23 | 9.87e-01 | 0.0802 |
| 3963 | LGALS7 | T3 | Human | Cervix | CC | 6.20e-12 | 3.96e-01 | 0.1389 |
| 3963 | LGALS7 | LZE4T | Human | Esophagus | ESCC | 7.27e-04 | -2.24e-01 | 0.0811 |
| 3963 | LGALS7 | LZE20T | Human | Esophagus | ESCC | 2.38e-09 | 1.52e+00 | 0.0662 |
| 3963 | LGALS7 | LZE22T | Human | Esophagus | ESCC | 1.49e-06 | 1.24e+00 | 0.068 |
| 3963 | LGALS7 | LZE24T | Human | Esophagus | ESCC | 5.89e-06 | 8.08e-01 | 0.0596 |
| 3963 | LGALS7 | LZE21T | Human | Esophagus | ESCC | 3.28e-09 | 3.29e+00 | 0.0655 |
| 3963 | LGALS7 | P1T-E | Human | Esophagus | ESCC | 1.78e-07 | 1.40e+00 | 0.0875 |
| 3963 | LGALS7 | P4T-E | Human | Esophagus | ESCC | 1.62e-19 | 1.19e+00 | 0.1323 |
| 3963 | LGALS7 | P5T-E | Human | Esophagus | ESCC | 2.95e-50 | 1.83e+00 | 0.1327 |
| 3963 | LGALS7 | P9T-E | Human | Esophagus | ESCC | 1.42e-42 | 2.34e+00 | 0.1131 |
| 3963 | LGALS7 | P10T-E | Human | Esophagus | ESCC | 4.57e-13 | 9.55e-01 | 0.116 |
| 3963 | LGALS7 | P11T-E | Human | Esophagus | ESCC | 1.56e-07 | 3.12e+00 | 0.1426 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
| GO:190303715 | Oral cavity | OSCC | regulation of leukocyte cell-cell adhesion | 162/7305 | 336/18723 | 3.39e-04 | 2.08e-03 | 162 |
| GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
| GO:004209816 | Oral cavity | OSCC | T cell proliferation | 100/7305 | 199/18723 | 7.93e-04 | 4.27e-03 | 100 |
| GO:00071629 | Oral cavity | OSCC | negative regulation of cell adhesion | 145/7305 | 303/18723 | 9.95e-04 | 5.18e-03 | 145 |
| GO:00466333 | Oral cavity | OSCC | alpha-beta T cell proliferation | 24/7305 | 38/18723 | 2.21e-03 | 1.00e-02 | 24 |
| GO:00466403 | Oral cavity | OSCC | regulation of alpha-beta T cell proliferation | 22/7305 | 35/18723 | 3.65e-03 | 1.51e-02 | 22 |
| GO:0046642 | Oral cavity | OSCC | negative regulation of alpha-beta T cell proliferation | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
| GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
| GO:0035739 | Oral cavity | OSCC | CD4-positive, alpha-beta T cell proliferation | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
| GO:2000561 | Oral cavity | OSCC | regulation of CD4-positive, alpha-beta T cell proliferation | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
| GO:00224086 | Oral cavity | OSCC | negative regulation of cell-cell adhesion | 92/7305 | 196/18723 | 1.41e-02 | 4.64e-02 | 92 |
| GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
| GO:004211017 | Oral cavity | LP | T cell activation | 146/4623 | 487/18723 | 4.13e-03 | 2.66e-02 | 146 |
| GO:000268315 | Oral cavity | LP | negative regulation of immune system process | 130/4623 | 434/18723 | 6.70e-03 | 3.90e-02 | 130 |
| GO:004211023 | Oral cavity | EOLP | T cell activation | 111/2218 | 487/18723 | 4.67e-12 | 8.17e-10 | 111 |
| GO:000715917 | Oral cavity | EOLP | leukocyte cell-cell adhesion | 86/2218 | 371/18723 | 5.01e-10 | 4.11e-08 | 86 |
| GO:005086316 | Oral cavity | EOLP | regulation of T cell activation | 76/2218 | 329/18723 | 5.96e-09 | 3.11e-07 | 76 |
| GO:190303716 | Oral cavity | EOLP | regulation of leukocyte cell-cell adhesion | 77/2218 | 336/18723 | 6.89e-09 | 3.53e-07 | 77 |
| GO:000268323 | Oral cavity | EOLP | negative regulation of immune system process | 91/2218 | 434/18723 | 3.12e-08 | 1.24e-06 | 91 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LGALS7 | SNV | Missense_Mutation | novel | c.215N>A | p.Arg72His | p.R72H | P47929 | protein_coding | tolerated(0.16) | benign(0.009) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| LGALS7 | SNV | Missense_Mutation | novel | c.96N>C | p.Arg32Ser | p.R32S | P47929 | protein_coding | tolerated(0.05) | possibly_damaging(0.476) | TCGA-DD-A1EL-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| LGALS7 | SNV | Missense_Mutation | novel | c.235N>T | p.Val79Phe | p.V79F | P47929 | protein_coding | tolerated(0.17) | benign(0.158) | TCGA-K7-A6G5-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |